



FINAL RELEASE

20 February 2007

**ANGEL BIOTECHNOLOGY HOLDINGS PLC  
("Angel" or "the Company")**

**Angel announces stem cell contract with CellGenea**

**Angel Biotechnology Holdings plc**, (AIM: ABH) the biopharmaceutical contract manufacturer, today announced the signing of a contract with the biotechnology company CellGenea. The contract is in the area of stem cell manufacturing, an area of particular expertise for Angel, and is expected to take approximately 12 months. Terms of the contract have not been disclosed.

**Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings plc, said:** "We are delighted to have entered into this contract with CellGenea, marrying CellGenea's research with Angel's stem cell manufacturing expertise. CellGenea's extensive contacts within the Greek healthcare system promise to provide exciting new opportunities for Angel in the area of stem cell therapies."

**Nikolaos Grigoriadis, Commercial Director of CellGenea, said:** "The opportunity to work with Angel Biotechnology, a company at the forefront of stem cell manufacturing, significantly strengthens the future of our company. Angel's demonstrated expertise in this area will ensure that CellGenea is able to provide the highest level of service to the Greek healthcare community."

**For further information, please call:**

**Angel Biotechnology Holdings plc**  
Gordon Sherriff – COO

Tel: +44 (0) 1670 591920  
Tel: +44 (0) 7951 057016

**About Angel Biotechnology Holdings plc**

Angel Biotechnology Holdings plc is a fast growing biomanufacturing company offering process development services and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.

Angel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo, SmithKline Beecham and Serologicals Inc.

Angel operates out of two sites, at Cramlington near Newcastle upon Tyne and at Pentlands Science Park, near Edinburgh.

Angel was established in 2000 and was admitted to trading on AIM in November 2005.

**About CellGenea**

CellGenea is a biotechnology company based in Thessaloniki, with offices throughout Greece. CellGenea is focussed on research, development and know-how in the fields of cellular biology, genetics, biochemistry and pharmacology. CellGenea uses the latest developments in genetic and biochemical analysis to offer individual patient consultation to improve the quality of life. CellGenea offers well-established services for collection and preservation of stem cells, based on specific protocols and directions acknowledged by the EU. CellGenea's experienced staff are

creating a rich patent portfolio based on developments within their own laboratories. CellGenea offers high quality services in the following areas:

- Information on the applications of stem cells to future parents and doctors.
- Immediate receipt of the sample throughout the year (52 weeks of the year, 7days a week).
- Analysis and preservation of the stem cells according to internationally acknowledged standards.
- Continuous control of the cryo-preserved samples.
- Immediate availability of the sample in case of a future therapeutic application for the child or any of the other family members.
- Full confidentiality and security for all personal data..